{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037882","form_type":"8-K/A","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.017620+00:00","generated_at":"2026-06-08T09:03:55.900463+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aadi Bioscience reports Q3 FYARRO sales $6M (+40% YoY); net loss $16.3M; PRECISION1 interim on track for Dec 2023","bullets":["FYARRO sales $6.0M in Q3 2023, up 40% YoY from $4.2M; net loss $16.3M vs $14.5M.","Cash, equivalents & investments $119.3M as of Sep 30, 2023, expected to fund operations into 2025.","PRECISION1 interim analysis on first third of patients (n=40) on track for mid-December 2023.","Dave Lennon appointed President and CEO in early October 2023.","Phase 2 trials initiated for endometrial cancer (nab-sirolimus + letrozole) and neuroendocrine tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037882","json":"https://secwatch.observer/filing/0001628280-23-037882.json","markdown":"https://secwatch.observer/filing/0001628280-23-037882.md","text":"https://secwatch.observer/filing/0001628280-23-037882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023037882/0001628280-23-037882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023037882/aadi-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:03:55.900463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a54e7d05a202b520d3df4c730a5cb629b4265f63","claim":"Whitehawk Therapeutics, Inc. reported the quarter ended September 30, 2023 results: revenue $6.0 million, net income $16.3 million.","evidence_excerpt":"total revenue resulting from sales of FYARRO for the quarter ended September 30, 2023, was $6.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023037882/0001628280-23-037882-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$6.0 million"},{"label":"Net income","value":"$16.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}